Becky
09-04-2006, 06:48 PM
This is very interesting especially when thinking about how these pathways may be interconnected.
Regards
Becky
-------------------------------------------------------------
NEW YORK (Reuters Health) - Trastuzumab (Herceptin) plus cisplatin is effective against breast cancer cells with low or undetectable HER-2 expression but with overexpression of the growth factor heregulin (HRG). In a study conducted at Northwestern University in Chicago, Illinois, researchers report that activation of HER-2 by HRG in breast cancers with low or undetectable HER-2 expression makes these tumors more resistant to cisplatin.
As reported in the August 10th Journal of Clinical Oncology, Dr. Ruth Lupu and colleagues engineered breast cancer cells with low HER-2 to overexpress HRG, which made them "10-fold more resistant to the alkylating agent cisplatin." The researchers found that co-exposure to trastuzumab completely reversed HRG-promoted resistance to chemo.
Trastuzumab is known to act synergistically with cisplatin and other agents such as docetaxel, paclitaxel and vinorelbine against HER-2-positive breast cancers. The team concludes this therapeutic approach can also be "extremely efficient without HER-2 overexpression."
Dr. Lupu told Reuters Health that "this is a completely new avenue of use of Herceptin in metastatic breast cancer."
Assessment of HRG expression could identify a breast cancer population with HER-2-negative tumors that might benefit from trastuzumab. "This approach makes about 30% more cases of breast cancer benefit from these chemotherapy agents," Dr. Lupu said.
Regards
Becky
-------------------------------------------------------------
NEW YORK (Reuters Health) - Trastuzumab (Herceptin) plus cisplatin is effective against breast cancer cells with low or undetectable HER-2 expression but with overexpression of the growth factor heregulin (HRG). In a study conducted at Northwestern University in Chicago, Illinois, researchers report that activation of HER-2 by HRG in breast cancers with low or undetectable HER-2 expression makes these tumors more resistant to cisplatin.
As reported in the August 10th Journal of Clinical Oncology, Dr. Ruth Lupu and colleagues engineered breast cancer cells with low HER-2 to overexpress HRG, which made them "10-fold more resistant to the alkylating agent cisplatin." The researchers found that co-exposure to trastuzumab completely reversed HRG-promoted resistance to chemo.
Trastuzumab is known to act synergistically with cisplatin and other agents such as docetaxel, paclitaxel and vinorelbine against HER-2-positive breast cancers. The team concludes this therapeutic approach can also be "extremely efficient without HER-2 overexpression."
Dr. Lupu told Reuters Health that "this is a completely new avenue of use of Herceptin in metastatic breast cancer."
Assessment of HRG expression could identify a breast cancer population with HER-2-negative tumors that might benefit from trastuzumab. "This approach makes about 30% more cases of breast cancer benefit from these chemotherapy agents," Dr. Lupu said.